

ICMJE DISCLOSURE FORM

Date: 3/7/2022

Your Name: Tina Vilsbøll

Manuscript Title: Redaktør for medicin.dk

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; height: 40px; margin-top: 5px;"> <tr><td style="width: 60%;"></td><td></td></tr> <tr><td></td><td style="text-align: right; font-size: small;">Click the tab key to add additional rows.</td></tr> </table>				Click the tab key to add additional rows.			
	Click the tab key to add additional rows.								
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 5px;"> <tr> <td style="width: 60%;">Novo Nordisk Foundation - Early interventions to prevent childhood overweight, spring 2021</td> <td><u>Project:</u> Healthy lifestyle before and during pregnancy to prevent childhood obesity - the PRE-STORK-trial</td> </tr> <tr> <td>Independent Research Fund Denmark 2021</td> <td><u>Project:</u> Cardiovascular effects of exercise-related hypoglycaemia and different plasma glucose decline rates in patients with type 1 diabetes ("Gluco-HEART")</td> </tr> <tr> <td>Novo Nordisk Foundation – COVID19, 2020</td> <td><u>Project:</u> The GLYCOVID-19 STUDY</td> </tr> </table>	Novo Nordisk Foundation - Early interventions to prevent childhood overweight, spring 2021	<u>Project:</u> Healthy lifestyle before and during pregnancy to prevent childhood obesity - the PRE-STORK-trial	Independent Research Fund Denmark 2021	<u>Project:</u> Cardiovascular effects of exercise-related hypoglycaemia and different plasma glucose decline rates in patients with type 1 diabetes ("Gluco-HEART")	Novo Nordisk Foundation – COVID19, 2020	<u>Project:</u> The GLYCOVID-19 STUDY	
Novo Nordisk Foundation - Early interventions to prevent childhood overweight, spring 2021	<u>Project:</u> Healthy lifestyle before and during pregnancy to prevent childhood obesity - the PRE-STORK-trial								
Independent Research Fund Denmark 2021	<u>Project:</u> Cardiovascular effects of exercise-related hypoglycaemia and different plasma glucose decline rates in patients with type 1 diabetes ("Gluco-HEART")								
Novo Nordisk Foundation – COVID19, 2020	<u>Project:</u> The GLYCOVID-19 STUDY								

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	<input type="checkbox"/> None	
		FaDLs forlag	Akutte Medicinske Tilstande (AMT) 2020 + 2022
		Gyldendal	Medicinsk kompenium (co-author)
4	Consulting fees	<input type="checkbox"/> None	
		Astra Zeneca	Novo Nordisk
		Boehringer Ingelheim	SunPharmaceutical
		Eli Lilly	Sanofi
		Mundipharma	GSK, Gilead, BMS
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	
		Astra Zeneca	Novo Nordisk
		Boehringer Ingelheim	Sanofi
		Eli Lilly	
		Mundipharma	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None	
		Novo Nordisk (advisory board 2019+)	Sanofi (advisory board 2019+)
		GSK (advisory board 202+)	Boehringer (advisory board 2019+)
		SunPharmaceutical (advisory board 2019+)	Lilly (advisory board 2019+)
10	Leadership or fiduciary role in other board,	<input checked="" type="checkbox"/> None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.